Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 58M | 432.7% |
| Gross Profit | -49M | 48% |
| Cost of Revenue | 108M | 2% |
| Operating expense | 178M | 0.7% |
| Net Income | -107M | 29.6% |
| EBITDA | -116M | 28.3% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 1.07B | 2.4% |
| Total Liabilities | 296M | 22% |
| Total Equity | 777M | 9.3% |
| Shares Outstanding | 22M | 9.7% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -67M | 50.4% |
| Cash from investing | -202M | 65.8% |
| Cash from financing | 7.5M | 94.4% |
EPS
Financial Highlights for Madrigal Pharmaceuticals in Q3 '24
Madrigal Pharmaceuticals reported a revenue of 58M, which is a 432.7% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at -49M, marking a 48% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 108M, a 2% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 178M, showing a 0.7% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -107M, showing a 29.6% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -116M, showing a 28.3% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Madrigal Pharmaceuticals with growth in revenue, gross profit, and net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
